Ameriprise Financial Inc. Reduces Stock Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Ameriprise Financial Inc. cut its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 5.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,806,866 shares of the company’s stock after selling 275,101 shares during the period. Ameriprise Financial Inc.’s holdings in GoodRx were worth $22,352,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. PDT Partners LLC purchased a new position in GoodRx in the fourth quarter valued at about $119,000. Northern Trust Corp grew its position in shares of GoodRx by 13.5% in the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company’s stock valued at $1,961,000 after purchasing an additional 50,256 shares during the last quarter. Oxford Asset Management LLP acquired a new stake in shares of GoodRx in the fourth quarter valued at approximately $75,000. Two Sigma Securities LLC acquired a new stake in shares of GoodRx in the fourth quarter valued at approximately $100,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of GoodRx by 28.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 255,192 shares of the company’s stock valued at $1,188,000 after purchasing an additional 56,522 shares during the last quarter. 63.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wells Fargo & Company lowered their price target on shares of GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 29th. The Goldman Sachs Group lowered their price target on shares of GoodRx from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, May 9th. UBS Group lowered their price target on shares of GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, Truist Financial lowered their price target on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a research report on Thursday, April 10th. Five analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $7.33.

GoodRx Stock Down 0.7%

Shares of NASDAQ GDRX opened at $4.27 on Thursday. GoodRx Holdings, Inc. has a 1 year low of $3.68 and a 1 year high of $9.26. The firm’s 50 day moving average price is $4.47 and its 200 day moving average price is $4.71. The firm has a market cap of $1.64 billion, a P/E ratio of -142.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.24. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The company had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. GoodRx’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the business earned $0.08 EPS. As a group, sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.